Lunai Bioworks (LNAI) Other Non-Current Assets (2012 - 2026)
Lunai Bioworks (LNAI) posted quarterly Other Non-Current Assets of $6.1 million for Q1 2026, down 94.62% year-over-year from $113.7 million in Q1 2025, and up 18094.88% quarter-over-quarter from $33608.0 in Q4 2025.
Lunai Bioworks (LNAI) Other Non-Current Assets (2012 - 2026) Analysis & Trends
Lunai Bioworks' Other Non-Current Assets history runs 15 years deep, the most recent figure standing at $6.1 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 94.62% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (down 94.62% YoY), while the FY2025 annual figure was $6.8 million, up 34241.1% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $6.1 million, up from $33608.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $167.8 million in Q1 2022, with the low at $19849.0 in Q2 2024.
- The 5-year median for Other Non-Current Assets is $6.8 million (2025), against an average of $42.6 million.
- Peak annual rise in Other Non-Current Assets reached 522689.75% in 2025, while the deepest fall reached 99.97% in 2025.
- Lunai Bioworks' Other Non-Current Assets stood at $74.3 million in 2022, then retreated by 25.85% to $55.1 million in 2023, then jumped by 98.14% to $109.2 million in 2024, then slumped by 99.97% to $33608.0 in 2025, then surged by 18094.88% to $6.1 million in 2026.
- Business Quant data shows LNAI's Other Non-Current Assets at $6.1 million in Q1 2026, $33608.0 in Q4 2025, and $6.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 | 6.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.11 Mn |
| Dec 31, 2025 | 33,608.00 |
| Sep 30, 2025 | 6.15 Mn |
| Jun 30, 2025 | 6.82 Mn |
| Mar 31, 2025 | 113.66 Mn |
| Dec 31, 2024 | 109.21 Mn |
| Sep 30, 2024 | 81,697.00 |
| Jun 30, 2024 | 19,849.00 |
| Mar 31, 2024 | 21,742.00 |
| Dec 31, 2023 | 55.12 Mn |
| Sep 30, 2023 | 55.17 Mn |
| Jun 30, 2023 | 55.23 Mn |
| Mar 31, 2023 | 58,586.00 |
| Dec 31, 2022 | 74.33 Mn |
| Sep 30, 2022 | 65,285.00 |
| Jun 30, 2022 | 74.48 Mn |
| Mar 31, 2022 | 167.76 Mn |
| Dec 31, 2021 | 31,494.00 |
| Sep 30, 2021 | 167.91 Mn |
| Jun 30, 2021 | 167.99 Mn |